{"pmid":32470232,"title":"Remdesivir and Potential Interactions With Psychotropic Medications: A COVID-19 Perspective.","text":["Remdesivir and Potential Interactions With Psychotropic Medications: A COVID-19 Perspective.","Prim Care Companion CNS Disord","Mansuri, Zeeshan","Shah, Bhumika","Zafar, Muhammad Khalid","Jolly, Taranjeet","Jain, Shailesh","32470232"],"journal":"Prim Care Companion CNS Disord","authors":["Mansuri, Zeeshan","Shah, Bhumika","Zafar, Muhammad Khalid","Jolly, Taranjeet","Jain, Shailesh"],"date":"2020-05-30T11:00:00Z","year":2020,"_id":"32470232","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.4088/PCC.20com02664","topics":["Treatment"],"weight":1,"_version_":1668167109984649216,"score":9.490897,"similar":[{"pmid":32446195,"title":"Interactions of recommended COVID-19 drugs with commonly used psychotropics.","text":["Interactions of recommended COVID-19 drugs with commonly used psychotropics.","Asian J Psychiatr","Chatterjee, Seshadri Sekhar","Malathesh, Barikar C","Das, Soumitra","Singh, Om Prakash","32446195"],"journal":"Asian J Psychiatr","authors":["Chatterjee, Seshadri Sekhar","Malathesh, Barikar C","Das, Soumitra","Singh, Om Prakash"],"date":"2020-05-24T11:00:00Z","year":2020,"_id":"32446195","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.ajp.2020.102173","keywords":["covid-19","drug interaction","hydroxychloroquine","psychotropics","ritonavir/lopinavir"],"topics":["Treatment"],"weight":1,"_version_":1667600475795488770,"score":55.71451},{"pmid":32402130,"title":"What do we know about remdesivir drug interactions?","text":["What do we know about remdesivir drug interactions?","The global pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-Co-V-2) has resulted in a critical need to rapidly develop new pharmacologic interventions and disseminate information. This has led to confusing and conflicting information on drug efficacy. Remdesivir has emerged as a promising treatment for SARS-Co-V-2 infection yet published clinical pharmacology and drug interaction studies are limited. Additional studies of the disposition of remdesivir, its active metabolite (GS-441524), and its triphosphate metabolite (GS-443902) are needed.","Clin Transl Sci","Yang, Katherine","32402130"],"abstract":["The global pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-Co-V-2) has resulted in a critical need to rapidly develop new pharmacologic interventions and disseminate information. This has led to confusing and conflicting information on drug efficacy. Remdesivir has emerged as a promising treatment for SARS-Co-V-2 infection yet published clinical pharmacology and drug interaction studies are limited. Additional studies of the disposition of remdesivir, its active metabolite (GS-441524), and its triphosphate metabolite (GS-443902) are needed."],"journal":"Clin Transl Sci","authors":["Yang, Katherine"],"date":"2020-05-14T11:00:00Z","year":2020,"_id":"32402130","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1111/cts.12815","locations":["metabolite","metabolite"],"topics":["Treatment"],"weight":1,"_version_":1666714494915575808,"score":44.82527}]}